Spinal and Biologics Business Overview

Spinal and Biologics accounted for $3.0 billion, or 22%, of Medtronic's $13.5 billion in revenue in FY2008.

FY2008 Global Revenue
Spinal and Biologics accounted for $3.0 billion, or 22%, of Medtronic's $13.5 billion in revenue in FY2008.

Spinal and Biologics is Medtronic's second-largest business. Our market leadership is largely a result of our innovation. We collaborate with world-renowned surgeons, researchers, and innovative partners to offer state-of-the-art therapies for spinal, neurological, orthopaedic, and oral maxillofacial conditions.

Our key product lines include:

  • Minimal access spinal systems for treating painful conditions of the spine, such as degenerative disc disease. We work hard to continually make our spinal systems less invasive, so surgery may be done with smaller incisions, more precision, less damage to the surrounding tissue, and faster recovery times.
  • Fusion systems that correct and stabilise abnormal spine curves.
  • Artificial cervical discs to replace damaged or degenerated discs in the neck.
  • A bone graft biologic that stimulates the body to regrow bone, eliminating the need to harvest bone from another area of the patient's body, thus preventing an additional, often painful, surgery.
Last updated: 27 Sep 2010

Section Navigation

Additional information

NYSE (MDT)

Australasia